Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Income towards Parent Company: 2011-2024

Historic Income towards Parent Company for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $673.7 million.

  • Agios Pharmaceuticals' Income towards Parent Company fell 110.91% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 160.06%. This contributed to the annual value of $673.7 million for FY2024, which is 291.35% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Income towards Parent Company stood at $673.7 million for FY2024, which was up 291.35% from -$352.1 million recorded in FY2023.
  • Over the past 5 years, Agios Pharmaceuticals' Income towards Parent Company peaked at $2.0 billion during FY2021, and registered a low of -$352.1 million during FY2023.
  • Over the past 3 years, Agios Pharmaceuticals' median Income towards Parent Company value was -$231.8 million (recorded in 2022), while the average stood at $29.9 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Income towards Parent Company soared by 101,255.30% in 2021, and later crashed by 111.82% in 2022.
  • Agios Pharmaceuticals' Income towards Parent Company (Yearly) stood at $1.9 million in 2020, then skyrocketed by 101,255.30% to $2.0 billion in 2021, then tumbled by 111.82% to -$231.8 million in 2022, then tumbled by 51.89% to -$352.1 million in 2023, then skyrocketed by 291.35% to $673.7 million in 2024.